353 related articles for article (PubMed ID: 28471669)
1. Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.
Gou Y; Zhang Y; Zhang Z; Wang J; Zhou Z; Liang H; Yang F
Mol Pharm; 2017 Jun; 14(6):1861-1873. PubMed ID: 28471669
[TBL] [Abstract][Full Text] [Related]
2. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer.
Gou Y; Zhang Y; Qi J; Chen S; Zhou Z; Wu X; Liang H; Yang F
Oncotarget; 2016 Oct; 7(41):67004-67019. PubMed ID: 27564255
[TBL] [Abstract][Full Text] [Related]
3. Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain.
Gou Y; Qi J; Ajayi JP; Zhang Y; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2015 Oct; 12(10):3597-609. PubMed ID: 26354410
[TBL] [Abstract][Full Text] [Related]
4. Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain.
Qi J; Zhang Y; Gou Y; Zhang Z; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 May; 13(5):1501-7. PubMed ID: 27017838
[TBL] [Abstract][Full Text] [Related]
5. Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin.
Wang J; Gou Y; Zhang Z; Yu P; Qi J; Qin Q; Sun H; Wu X; Liang H; Yang F
Mol Pharm; 2018 Jun; 15(6):2180-2193. PubMed ID: 29722993
[TBL] [Abstract][Full Text] [Related]
6. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin.
Zhang Y; Zhang Z; Gou Y; Jiang M; Khan H; Zhou Z; Liang H; Yang F
J Inorg Biochem; 2017 Jul; 172():1-8. PubMed ID: 28395195
[TBL] [Abstract][Full Text] [Related]
7. Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain.
Qi J; Gou Y; Zhang Y; Yang K; Chen S; Liu L; Wu X; Wang T; Zhang W; Yang F
J Med Chem; 2016 Aug; 59(16):7497-511. PubMed ID: 27441502
[TBL] [Abstract][Full Text] [Related]
8. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Gou Y; Zhang Z; Qi J; Liang S; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Dec; 153():13-22. PubMed ID: 26398432
[TBL] [Abstract][Full Text] [Related]
9. Protein binding studies with human serum albumin, molecular docking and in vitro cytotoxicity studies using HeLa cervical carcinoma cells of Cu(ii)/Zn(ii) complexes containing a carbohydrazone ligand.
Parsekar SU; Velankanni P; Sridhar S; Haldar P; Mate NA; Banerjee A; Sudhadevi Antharjanam PK; Koley AP; Kumar M
Dalton Trans; 2020 Mar; 49(9):2947-2965. PubMed ID: 32073070
[TBL] [Abstract][Full Text] [Related]
10. Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment.
Zhang Z; Zhang J; Jiang M; Zhao L; Li S; Sun H; Yang F; Liang H
Mol Pharm; 2020 Apr; 17(4):1405-1414. PubMed ID: 32096645
[TBL] [Abstract][Full Text] [Related]
11. Designing biotin-human serum albumin nanoparticles to enhance the targeting ability of binuclear ruthenium(III) compound.
Jiang M; Li S; Wu J; Li W; Wen XA; Liang H; Yang F
J Inorg Biochem; 2021 Feb; 215():111318. PubMed ID: 33301985
[TBL] [Abstract][Full Text] [Related]
12. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model.
Gou Y; Zhang Z; Li D; Zhao L; Cai M; Sun Z; Li Y; Zhang Y; Khan H; Sun H; Wang T; Liang H; Yang F
Drug Deliv; 2018 Nov; 25(1):321-329. PubMed ID: 29350051
[TBL] [Abstract][Full Text] [Related]
13. Folate-conjugated human serum albumin-encapsulated resveratrol nanoparticles: preparation, characterization, bioavailability and targeting of liver tumors.
Lian B; Wu M; Feng Z; Deng Y; Zhong C; Zhao X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):154-165. PubMed ID: 30686050
[TBL] [Abstract][Full Text] [Related]
14. Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
Qi J; Zhang Y; Gou Y; Lee P; Wang J; Chen S; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 Sep; 13(9):3098-105. PubMed ID: 27453125
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Tissue Distribution of Folate-Decorated Human Serum Albumin Loaded With Nano-Hydroxycamptothecin for Tumor Targeting.
Wang W; Liang H; Sun B; Xu J; Zeng Z; Zhao X; Li Q
J Pharm Sci; 2016 Jun; 105(6):1874-1880. PubMed ID: 27129905
[TBL] [Abstract][Full Text] [Related]
16. Human Serum Albumin-Platinum(II) Agent Nanoparticles Inhibit Tumor Growth Through Multimodal Action Against the Tumor Microenvironment.
Xu S; Luo W; Zhu M; Zhao L; Gao L; Liang H; Zhang Z; Yang F
Mol Pharm; 2024 Jan; 21(1):346-357. PubMed ID: 38015620
[TBL] [Abstract][Full Text] [Related]
17. Mixed-ligand copper(ii) Schiff base complexes: the role of the co-ligand in DNA binding, DNA cleavage, protein binding and cytotoxicity.
Lian WJ; Wang XT; Xie CZ; Tian H; Song XQ; Pan HT; Qiao X; Xu JY
Dalton Trans; 2016 May; 45(22):9073-87. PubMed ID: 27163172
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin.
Gou Y; Zhang Y; Qi J; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Mar; 144():47-55. PubMed ID: 25573806
[TBL] [Abstract][Full Text] [Related]
19. Developing a Multitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin.
Li W; Li S; Zhang Z; Xu G; Man X; Yang F; Liang H
J Med Chem; 2023 Jul; 66(13):8564-8579. PubMed ID: 37321208
[TBL] [Abstract][Full Text] [Related]
20. Folate receptor alpha targeted delivery of artemether to breast cancer cells with folate-decorated human serum albumin nanoparticles.
Akbarian A; Ebtekar M; Pakravan N; Hassan ZM
Int J Biol Macromol; 2020 Jun; 152():90-101. PubMed ID: 32057865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
